DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 444 in DePuy Orthopaedics

  1. One Put, One Call Option To Know About for Johnson & JohnsonRead the original story

    Monday | Forbes.com

    Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .

    Comment?

  2. DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf...Read the original story w/Photo

    Saturday Jul 26 | PRWeb

    ... litigation shows there are currently 6,207 DePuy Pinnacle lawsuits pending, as of July 15, 2014. (In Re: DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation, MDL No. 2244) [jpml.uscour ...

    Comment?

  3. First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge...Read the original story w/Photo

    Friday Jul 25 | PRWeb

    ... ruled that the two Plaintiffs' claims may proceed to trial against Johnson & Johnson, the parent of DePuy Orthopaedics, and several affiliates. (Lay v. DePuy Orthopaedics Inc., et al., No. 11-3590; Herlihy-Paoli v. DePuy Orthopaedics Inc., et al., ...

    Comment?

  4. Johnson & Johnson partners with Organovo to consider 3D-printing living tissueRead the original story w/Photo

    Thursday Jul 24 | GigaOM

    The partnership centers around using bioprinted tissue to discover new drugs. The announcement comes ahead of Organovo's commercial launch later this year.

    Comment?

  5. CHMP's positive on Imbruvica for blood cancerRead the original story

    Friday Jul 25 | Seeking Alpha

    The EMA's Committee for Medicinal Products for Human Use adopt a positive opinion supporting approval of Imbruvica as a treatment for adult patients with relapsed or refractory mantle cell lymphoma or adult patients with chronic lymphocytic leukemia who have received at least one prior therapy or as a first-line treatment in patients with the 17p ... (more)

    Comment?

  6. What's best for baby?Read the original story w/Photo

    Wednesday Jul 23 | The New Zealand Herald

    Sharon Dowling, research and development manager for leading company Johnson & Johnson , shares her advice.

    Comment?

  7. DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies...Read the original story w/Photo

    Wednesday Jul 23 | PRWeb

    ... Plaintiff had shown that 80%-to-90% of hospitals charge nothing to return explanted devices. (Russell v. DePuy Orthopaedics Inc., et al., No. 13-3518) "Our Firm is representing numerous clients who have filed Pinnacle hip lawsuits in this ...

    Comment?

  8. Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014Read the original story

    Wednesday Jul 23 | Hispanic Business

    We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people.

    Comment?

  9. 3 Quotes From Johnson & Johnson's Conference Call You Need to ReadRead the original story

    Tuesday Jul 22 | The Motley Fool

    Here are three quotes from the call and some commentary about why they're so important.

    Comment?

  10. Why Johnson & Johnson (JNJ) Stock Is Up TodayRead the original story w/Photo

    Tuesday Jul 22 | TheStreet.com

    The timetable for the buybacks is open ended and left up to the discretion of the company's management.

    Comment?

  11. Atlas biotech gets $29M to create healing bacteria for the gutRead the original story w/Photo

    Tuesday Jul 22 | Business Journal

    Eight months after Flagship Ventures launched its biotech to develop drugs based on microorganisms in the human body, Atlas Venture today announced $29 million in financing for its entry into that field.

    Comment?

  12. J&J Buying Back $5B Worth of its SharesRead the original story w/Photo

    Monday Jul 21 | Pharmaceutical Processing

    Johnson & Johnson, the world's biggest maker of health care products, plans to buy back up to $5 billion of the company's common stock.

    Comment?

  13. Strides Arcolab acquires majority stake in Bafna PharmaRead the original story

    Monday Jul 21 | DNA India

    Bangalore-based Strides Arcolab, on Monday, said it has entered into an agreement with Chennai-based Bafna Pharmaceuticals to acquire majority stake of its branded generic business for a cash consideration of Rs 48.1 crore.

    Comment?

  14. Johnson & Johnson sets $5 bln share buybackRead the original story w/Photo

    Monday Jul 21 | MarketWatch

    Timing of the buybacks is open ended and will be left to the discretion of management.

    Comment?

  15. Johnson & Johnson (JNJ) Declares 70c Quarterly DividendRead the original story w/Photo

    Monday Jul 21 | TheStreet.com

    The quarterly dividend is in line with the company's previous. The dividend is payable on Sept.

    Comment?

  16. One Put, One Call Option To Know About for Johnson & JohnsonRead the original story

    Monday Jul 21 | Forbes.com

    Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .

    Comment?

  17. Federal DePuy ASR Litigation Schedules July Conference to Discuss...Read the original story w/Photo

    Saturday Jul 19 | PRWeb

    ... and matters related to a DePuy settlement agreement proposed last year, court records indicate. (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation - MDL 2197) "As our Firm continues to represent numerous individuals in ...

    Comment?

  18. Health care industry investments can create healthy portfolioRead the original story w/Photo

    Friday Jul 18 | NewsOK.com

    Dear Mr. Berko: I like your column because it also makes me laugh, but one big criticism I have is that you never follow up to advise people when to sell the stocks you recommend.

    Comment?

  19. XLV, RZG: Big ETF OutflowsRead the original story w/Photo

    Thursday Jul 17 | Forbes.com

    Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Health Care Select Sector SPDR Fund , where 4,800,000 units were destroyed, or a 3.0% decrease week over week.

    Comment?

  20. Johnson & Johnson Given "Neutral" Rating at ZacksRead the original story

    Wednesday Jul 16 | AmericanBankingNews.com

    's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Wednesday.

    Comment?